A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CBP-201 Administered to Healthy Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 16 Jul 2019
Price : $35 *
At a glance
- Drugs CBP-201 (Primary) ; CBP-201 (Primary)
- Indications Asthma; Atopic dermatitis; Nasal polyps
- Focus Adverse reactions; First in man
- 06 May 2019 Results published in the Connect Biopharma Media Release
- 06 May 2019 Status changed from active, no longer recruiting to completed, as reported in a Connect Biopharma media release.
- 09 Jan 2019 Status changed from not yet recruiting to active, no longer recruiting.